18F-FDG PET/CT and Molecular Tumor Characterisation for Staging and Follow-up of Colon Cancer
Not Applicable
- Conditions
- Colon Cancer
- Registration Number
- NCT01636674
- Lead Sponsor
- Naestved Hospital
- Brief Summary
The investigators are investigating the usefulness of 18F-Fluordeoxyglucose Positron Emission Tomography/ Computed Tomography (18F-FDG PET/CT) for staging and follow-up of colon cancer. Furthermore, the investigators combine 18F-FDG PET findings with clinical and histopathological features, circulating tumor cell (CTC) analyses, tumor gene expression and measurements of circulating cancer biomarkers sUPAR, TIMP-1 and CEA in order to predict tumor recurrence.
The investigators hypothesis: The combination of functional imaging by 18F-FDG PET/CT and pre-existing and evolving molecular biomarkers will optimize tumor characterization, staging of disease and early detection of recurrence.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 66
Inclusion Criteria
- clinical or histological diagnosis of malignant clonic neoplasm (distance of more than 15 cm from anal ring)
- 18 years of age or older
- written informed consent
Exclusion Criteria
- diabetes
- known malignant disease other than colon cancer
- known metastatic disease
- impairment of renal function
- allergy to CT contrast agents
- body weight of more than 150 kg
- claustrophobia
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method time to recurrence
- Secondary Outcome Measures
Name Time Method